DGIdb - BICALUTAMIDE Drug Record

BICALUTAMIDE chembl:CHEMBL409 ApprovedAntineoplastic

Alternate Names:

COSUDEX
ICI-176334
BICALUTAMIDE
ICI176,334-1
CALUTIDE
KALUMID
CASODEX
CASODEX®
ZD7054
CALUTIDE®
BICALUTAMIDUM
ICI 176334
BICALUTAMIDA
pubchem.compound:2375
rxcui:83008
drugbank:01128
chemidplus:90357-06-5
chembl:CHEMBL409

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Year of Approval	1995
Drug Class	antineoplastic agents

(4 More Sources)

Publications:

Wang et al., 1998, Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor., Biochem. Pharmacol.
Bouchal et al., 2002, The effects of natural ligands of hormone receptors and their antagonists on telomerase activity in the androgen sensitive prostatic cancer cell line LNCaP., Biochem. Pharmacol.
Laufer et al., 1999, Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer., Urology
Hara et al., 2003, Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome., Cancer Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Chang et al., 1999, Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells., Proc. Natl. Acad. Sci. U.S.A.
Liu W et al., 2012, Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A., J Med Chem
Yoshino H et al., 2010, Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Bioorg Med Chem
Yoshino H et al., 2010, Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists., Bioorg Med Chem
Weiser PT et al., 2012, 3,3'-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding., Bioorg Med Chem Lett
Robinson et al., 2015, Integrative clinical genomics of advanced prostate cancer., Cell
Fushimi C et al., 2018, A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma., Ann Oncol
Madarová et al., 2001, Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide., Neoplasma
McCourt et al., 2012, Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy., Clin. Cancer Res.
McKillop et al., 1998, Enzyme-inducing effects of bicalutamide in mouse, rat and dog., Xenobiotica
Fujii et al., 2004, Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells., Am. J. Physiol. Endocrinol. Metab.
Sadar, 1999, Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways., J. Biol. Chem.

BICALUTAMIDE FST

Interaction Score: 10.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14761877

Sources:
NCI
BICALUTAMIDE CFLAR

Interaction Score: 2.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22623731

Sources:
CIViC
BICALUTAMIDE KLK3

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10075669

Sources:
NCI
BICALUTAMIDE CYP2B6

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9622849

Sources:
NCI
BICALUTAMIDE BAX

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11845989

Sources:
NCI
BICALUTAMIDE AR

Interaction Score: 0.22

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name bicalutimide,Casodex

Novel drug target Established target

Mechanism of Interaction Androgen Receptor antagonist

PMIDs:
10076535 11931851 10754148 12517791 11752352 10500149 22175694 21050768 20381361 23017882 26000489 29211833

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND CIViC TTD

TEND: BICALUTAMIDE
- Version: 01-August-2011
Alternate Names:

BICALUTAMIDE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1995

Publications:
TdgClinicalTrial: BICALUTAMIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: BICALUTAMIDE

Version: 14-September-2017

Alternate Names:

C1599 NCI drug code

Drug Info:

Publications:

Madarová et al., 2001, Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide., Neoplasma

McKillop et al., 1998, Enzyme-inducing effects of bicalutamide in mouse, rat and dog., Xenobiotica

Fujii et al., 2004, Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells., Am. J. Physiol. Endocrinol. Metab.

DTC: BICALUTAMIDE

Version: 02-September-2020

Alternate Names:

CHEMBL409 ChEMBL Drug ID

Drug Info:

Publications:

Yoshino H et al., 2010, Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists., Bioorg Med Chem

Weiser PT et al., 2012, 3,3'-Disubstituted bipolar biphenyls as inhibitors of nuclear receptor coactivator binding., Bioorg Med Chem Lett

Yoshino H et al., 2010, Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Bioorg Med Chem

CIViC: BICALUTAMIDE

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Hara et al., 2003, Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome., Cancer Res.

Robinson et al., 2015, Integrative clinical genomics of advanced prostate cancer., Cell

Fushimi C et al., 2018, A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma., Ann Oncol

TTD: Bicalutamide
- Version: 2020.06.01
Alternate Names:

D0V9BD TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL409
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL409
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	bicalutimide,Casodex
Novel drug target	Established target
Mechanism of Interaction	Androgen Receptor antagonist

BICALUTAMIDE Drug Record

BICALUTAMIDE chembl:CHEMBL409 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

BICALUTAMIDE FST

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14761877

Sources: NCI

BICALUTAMIDE CFLAR

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22623731

Sources: CIViC

BICALUTAMIDE KLK3

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10075669

Sources: NCI

BICALUTAMIDE CYP2B6

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9622849

Sources: NCI

BICALUTAMIDE BAX

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11845989

Sources: NCI

BICALUTAMIDE AR

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name bicalutimide,Casodex Novel drug target Established target Mechanism of Interaction Androgen Receptor antagonist

PMIDs: 10076535 11931851 10754148 12517791 11752352 10500149 22175694 21050768 20381361 23017882 26000489 29211833

Sources: DTC TdgClinicalTrial ChemblInteractions TEND CIViC TTD

TEND: BICALUTAMIDE

Alternate Names: BICALUTAMIDE Primary Drug Name

Drug Info: Drug Class antineoplastic agents Year of Approval 1995

Publications:

TdgClinicalTrial: BICALUTAMIDE

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small Molecule FDA Approval approved

Publications:

NCI: BICALUTAMIDE

Alternate Names: C1599 NCI drug code

Drug Info:

DTC: BICALUTAMIDE

Alternate Names: CHEMBL409 ChEMBL Drug ID

Drug Info:

CIViC: BICALUTAMIDE

Alternate Names:

Drug Info:

TTD: Bicalutamide

Alternate Names: D0V9BD TTD Drug ID

Drug Info:

Publications:

ChemblInteractions: CHEMBL409

Alternate Names:

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL409

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
14761877

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22623731

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
10075669

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9622849

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11845989

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name bicalutimide,Casodex

Novel drug target Established target

Mechanism of Interaction Androgen Receptor antagonist

PMIDs:
10076535 11931851 10754148 12517791 11752352 10500149 22175694 21050768 20381361 23017882 26000489 29211833

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND CIViC TTD

Alternate Names:

BICALUTAMIDE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1995

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

C1599 NCI drug code

Alternate Names:

CHEMBL409 ChEMBL Drug ID

Alternate Names:

D0V9BD TTD Drug ID